重组人干扰素α-1b联合布地奈德雾化治疗上呼吸道感染患儿的效果及对炎症因子的影响

doi:10.3969/j.issn.1671-7171.2026.08.020

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1162 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the efficacy of nebulized recombinant human interferon α-1b combined with budesonide in children with upper respiratory tract infection and its effect on inflammatory factors. 【Methods】 A total of 132 children with upper respiratory tract infection treated in Wugang Traditional Chinese Medicine Hospital from January 2023 to May 2025 were enrolled and randomly divided into control group and observation group by random number table method, with 66 cases in each group. The control group received nebulized budesonide, while the observation group was treated with nebulized budesonide combined with recombinant human interferon α-1b. The time for symptom resolution, adverse reactions, as well as the levels of inflammatory factors and immunoglobulins before and after treatment were compared between the two groups. 【Results】 After treatment, the resolution time of fever, cough, wheezing and rales in the observation group were shorter than those in the control group (all P<0.05). After treatment, serum immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) levels in the observation group were higher than those in the control group (all P<0.05), whereas serum immunoglobulin E (IgE) level was lower. After treatment, serum interleukin-2 (IL-2) and interferon γ (IFN-γ) levels in the observation group were higher (all P<0.05), while serum interleukin-4 (IL-4) and interleukin-10 (IL-10) levels were lower (all P<0.05). The total incidence of adverse reactions in the observation group was 6.06%, which was significantly lower than 25.76% in the control group (P<0.05). 【Conclusion】 Nebulized recombinant human interferon α-1b combined with budesonide can shorten symptom resolution time, effectively regulate serum immunoglobulin and inflammatory factor levels, and presents favorable safety in children with upper respiratory tract infection.

Key words： Respiratory Tract Infections Interferon α-1b Budesonide Inflammatory Factor Child

Received: 19 November 2025

PACS:

R725.176

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiaole

Cite this article:

LI Xiaole. Efficacy of Recombinant Human Interferon α-1b Combined with Budesonide in the Treatment of Children with Upper Respiratory Tract Infection and its Influence on Inflammatory Factors[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1306-1308.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.08.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I8/1306

[1] Cao L, Ma Y Y, Wan Z Z, et al. Longitudinal anellome dynamics in the upper respiratory tract of children with acute respiratory tract infections[J]. Virus Evol, 2023, 9(2): vead045.
[2] Shen H N, Zhao X N, Xu L Y. Meta-analysis of the efficacy of budesonide and ambroxol hydrochloride inhalation in children with pneumonia and their effects on inflammatory response[J]. Heliyon, 2023, 9(11):e21105.
[3] Chen J, Zhu Y, Zheng C F, et al. Clinical efficacy of budesonide combined with acetylcysteine in the treatment of mycoplasma pneumonia infection[J]. Immun Inflamm Dis, 2023, 11(11): e1068.
[4] 胡亚美,江载芳,诸福棠.实用儿科学[M].7版.北京:人民卫生出版社,2003:1204-1205.
[5] 尹小梅,袁珂,王健,等. 难治性哮喘患儿个体化治疗的临床研究[J]. 中国临床药理学杂志,2023,39(17):2540-2543.
[6] 章邱东,梅晓冬. 布地格福吸入气雾剂治疗中、重度慢性阻塞性肺疾病患者的临床研究[J]. 中国临床药理学杂志,2022,38(3):203-206.
[7] 赵敏,杨华,宫晶. 重组人干扰素α-1b对RSV感染性肺炎患儿免疫及TLR4蛋白表达的影响[J]. 国际呼吸杂志,2022,42(16):1220-1224.
[8] 董伟然,张燕,安会波,等. 吸入用布地奈德联合重组人干扰素α-1b注射液雾化干预对呼吸道合胞病毒感染幼鼠模型血清白介素13水平及CD2⁺T淋巴细胞占比的影响[J]. 实用心脑肺血管病杂志,2022,30(10):75-80.
[9] 董伟然,张燕,安会波,等. 重组人干扰素α-1b联合布地奈德对呼吸道合胞病毒感染大鼠血清、肺泡灌洗液白介素-4水平的影响[J]. 河北医药,2022,44(13):1966-1969.
[10] Majumdar A, Saha R, Chatterjee A, et al. Upsurge in hospitalization of pediatric patients with severe acute respiratory infections in Kolkata and surrounding districts caused by recombinant human respiratory adenovirus type B 7/3[J]. J Med Virol, 2023, 95(7): e28897.
[11] Lee A C, Jeong Y, Lee S, et al. Nasopharyngeal type-I interferon for immediately available prophylaxis against emerging respiratory viral infections[J]. Front Immunol, 2021, 12: 660298.
[12] 李青,梁宽,胡梦娇,等. 重组人干扰素α1b雾化吸入联合布地奈德治疗儿童反复上呼吸道感染的临床疗效及对免疫功能的影响[J]. 海南医学,2023,34(6):818-821.
[13] 郭长江,冷建刚,邵伟. 阿莫西林克拉维酸钾联合布地奈德治疗小儿反复细菌性呼吸道感染[J]. 中华肺部疾病杂志(电子版),2023,16(3):394-396.
[14] 储开东,邵志莉,袁伯稳. 重组人干扰素 α1b联合更昔洛韦对传染性单核细胞增多症合并肝功能异常患儿炎症免疫和肝功能的影响[J]. 中国医院用药评价与分析,2023,23(4):443-446.
[15] 常秀,赵静,侯召权,等. 基于TLR3/TRIF通路分析重组人干扰素α2b联合炎琥宁对病毒性肺炎患儿的疗效与作用机制[J]. 临床误诊误治,2023,36(2):128-132.